Skip to search formSkip to main contentSkip to account menu

PX20606

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Faculty of 1000 evaluation for The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
2016
2016
The non-steroidal FXR agonists PX20606 and GS-9674 improve liver fibrosis and portal hypertension in rodent models of cholestatic, metabolic and toxic liver cirrhosis
2015
2015
P0271 : Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease
2014
2014
P43 THE SYNTHETIC FXR AGONIST PX20606 ATTENUATES BACTERIAL TRANSLOCATION, INTESTINAL INFLAMMATION, AND REDUCES SPLANCHNIC BLOOD FLOW IN PORTAL HYPERTENSIVE MICE
2014
2014
Combination treatment of the novel pharmacological fxr-compound px20606 and ezetimibe leads to massively increased neutral sterols excretion in mice
2014
2014
The synthetic FXR agonist PX20606 attenuates bacterial translocation, intestinal inflammation, and reduces splanchnic blood flow in portal hypertensive mice
2012
2012
Synthetic FXR agonist Px20606 lowers cholesterol in HDL2 but not in HDL3 subfractions and demonstrates anti-atherosclerotic effects
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)